CMA has today published the Regulatory Outcomes Report 2025, offering a comprehensive overview of the regulatory priorities, progress and outcomes achieved by CMA on behalf of members over the past 18 months.

The report details our work across a broad range of regulatory matters, including ingredient access, labelling reform, GMP processes, packaging updates and product viability. It highlights the significant behind-the-scenes advocacy undertaken to ensure regulation remains proportionate, risk-based and supportive of innovation — while helping members avoid unnecessary costs and disruption.

As the complementary medicines industry continues to operate in one of the most tightly regulated therapeutic goods environments globally, the importance of clear, strategic advocacy has never been greater.

“Through expert engagement, evidence-based submissions and strategic advocacy, we’ve delivered outcomes that preserve access, reduce regulatory burden, and support member success,” said CMA Chief Executive Officer John O’Doherty.

“This Regulatory Outcomes Report highlights the value and impact of that work – and demonstrates why CMA’s role remains critical in ensuring the complementary medicines sector can continue to thrive in a complex and evolving regulatory environment.”

The Regulatory Outcomes Report 2025 is available to view or download here.